American Society of Hematology

Figure 1

$Figure 1. PRAME expression in leukemia cell lines and patient samples. (A) PRAME expression increases with CML disease progression. PRAME expression is shown as the log10 ratio of the normalized expression of PRAME in each patient sample compared with PRAME expression in a pool of CML CP samples. Red bars represent CP patients (n = 42); green bars represent patients with either AP disease by virtue of additional cytogenetic abnormalities (cAP; n = 7) or patients who returned to CP after treatment for BC disease (last 3); dark blue bars represent patients with AP disease by both cytogenetic and blast count criteria (n = 10); and light blue represents BC patients (n = 28). The difference between CP and BC is statistically significant (P << .001). (B) PRAME expression in normal and malignant hematopoietic cells. Normalized PRAME expression is shown on a log2 scale. PRAME was heterogeneously expressed in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients with either refractory anemia with excess blasts or refractory anemia with excess blasts in transition. From left to right: CD34+ selected bone marrow (BM; red, n = 8), CD34+ selected peripheral blood stem cell products (light green, n = 10), unsorted BM (medium blue, n = 10), unsorted peripheral blood (light blue, n = 10), MDS (brown, n = 29), AML (green, n = 26), CP CML (purple, n = 17 independent cases from those shown in A), B-ALL (medium blue, n = 32), and T-ALL (pink, n = 7). (C) Quantitative PCR validation of PRAME expression in independent diagnostic BM samples from BC (n = 31) and early CP (n = 58) CML patients demonstrates increased expression in BC. Data are shown on a logarithmic (log10) scale. The line within each box represents the median; the upper and lower lines defining the box represent the 75th and 25th percentiles, respectively; and the lines outside the box extend to the maximum and minimum values (10−1 indicates undetectable PRAME expression). PRAME was expressed in all but 1 BC patient and in 50% of the CP patients. Mean expression was 9.0 × 104 copies (median, 5.5 × 104; range, 0 to 1.6 × 106 copies) in BC patients versus 560 copies (median, 200; range, 0 to 9.8 × 103 copies) in CP patients (P < .001).$

PRAME expression in leukemia cell lines and patient samples. (A) PRAME expression increases with CML disease progression. PRAME expression is shown as the log₁₀ ratio of the normalized expression of PRAME in each patient sample compared with PRAME expression in a pool of CML CP samples. Red bars represent CP patients (n = 42); green bars represent patients with either AP disease by virtue of additional cytogenetic abnormalities (cAP; n = 7) or patients who returned to CP after treatment for BC disease (last 3); dark blue bars represent patients with AP disease by both cytogenetic and blast count criteria (n = 10); and light blue represents BC patients (n = 28). The difference between CP and BC is statistically significant (P << .001). (B) PRAME expression in normal and malignant hematopoietic cells. Normalized PRAME expression is shown on a log₂ scale. PRAME was heterogeneously expressed in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients with either refractory anemia with excess blasts or refractory anemia with excess blasts in transition. From left to right: CD34⁺ selected bone marrow (BM; red, n = 8), CD34⁺ selected peripheral blood stem cell products (light green, n = 10), unsorted BM (medium blue, n = 10), unsorted peripheral blood (light blue, n = 10), MDS (brown, n = 29), AML (green, n = 26), CP CML (purple, n = 17 independent cases from those shown in A), B-ALL (medium blue, n = 32), and T-ALL (pink, n = 7). (C) Quantitative PCR validation of PRAME expression in independent diagnostic BM samples from BC (n = 31) and early CP (n = 58) CML patients demonstrates increased expression in BC. Data are shown on a logarithmic (log₁₀) scale. The line within each box represents the median; the upper and lower lines defining the box represent the 75th and 25th percentiles, respectively; and the lines outside the box extend to the maximum and minimum values (10⁻¹ indicates undetectable PRAME expression). PRAME was expressed in all but 1 BC patient and in 50% of the CP patients. Mean expression was 9.0 × 10⁴ copies (median, 5.5 × 10⁴; range, 0 to 1.6 × 10⁶ copies) in BC patients versus 560 copies (median, 200; range, 0 to 9.8 × 10³ copies) in CP patients (P < .001).

This Feature Is Available To Subscribers Only